• Profile
Close

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: A prespecified analysis from the randomized, phase III SYNERGY II study

Neurourology and Urodynamics Jan 24, 2019

Muelle ER, et al. - In this prespecified analysis from the randomized, phase III SYNERGY II study, a total of 1794 subjects of age ≥18 years were assessed to investigate the safety and efficiency of the combination of mirabegron and solifenacin vs each monotherapy among older candidates with overactive bladder (OAB). About 47.2% of individuals were observed with ≥1 treatment-emergent adverse events (TEAE). Researchers recorded an increase in mean pulse rate of >1 bpm from baseline in the younger age groups with combination therapy and mirabegron (monotherapy) only. Overall, they concluded mirabegron and solifenacin combination therapy, well-tolerated and efficient for subjects with OAB symptoms irrespective of their age.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay